Drugs / TAA-specific CTLs
TAA-specific CTLs
also known as
TAA-CTLs · TAA-specific cytotoxic T lymphocytes · tumor-associated antigen (TAA)-specific cytotoxic T lymphocytes
Cell therapy targets MAGEA4, PRAME, SSX2 via depletion
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT05134740 | Apr 2024 → Feb 2025 | Hodgkins lymphoma, non-Hodgkin lymphoma | Baylor College of Medicine | Withdrawn | No outcome recorded |
| Phase 1 | NCT02291848 | Apr 2015 → Dec 2026 expected | plasma cell myeloma | Baylor College of Medicine | Recruiting | No outcome recorded |
| Phase 1 | NCT02239861 | Apr 2015 → Oct 2018 | rhabdomyosarcoma | Baylor College of Medicine | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT03093350 | Oct 2017 → May 2019 | breast cancer | Baylor College of Medicine | Completed | No outcome recorded |
Evidence & citations 10 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TAA-Specific CTLs | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02239861 ↗ |
| Known as | TAA-CTLs | “These TAA-specific cytotoxic T lymphocytes (TAA-CTLs) are an investigational product not approved by the Food and Drug Administration.” NCT03093350 ↗ |
| Known as | TAA-specific cytotoxic T lymphocytes | “These TAA-specific cytotoxic T lymphocytes (TAA-CTLs) are an investigational product not approved by the Food and Drug Administration.” NCT03093350 ↗ |
| Known as | tumor-associated antigen (TAA)-specific cytotoxic T lymphocytes | “special immune system cells called tumor-associated antigen (TAA)-specific cytotoxic T lymphocytes” NCT03093350 ↗ |
| Action | Deplete | “This helps to train the T cells to kill cells with TAAs on their surface.” NCT02291848 ↗ |
| Modality | Cell therapy | “special immune system cells called tumor-associated antigen (TAA)-specific cytotoxic T lymphocytes, a new experimental therapy” NCT02239861 ↗ |
| Route | Intravenous | “given by intravenous injection” NCT02239861 ↗ |
| Target | MAGEA4 | “In this study, investigators target five common TAAs. They are called NY-ESO-1, MAGEA4, PRAME, Survivin and SSX2.” NCT03093350 ↗ |
| Target | PRAME | “In this study, investigators target five common TAAs. They are called NY-ESO-1, MAGEA4, PRAME, Survivin and SSX2.” NCT03093350 ↗ |
| Target | SSX2 | “In this study, investigators target five common TAAs. They are called NY-ESO-1, MAGEA4, PRAME, Survivin and SSX2.” NCT03093350 ↗ |